| Literature DB >> 27609808 |
Christoph Höner Zu Siederdissen1, Franziska Rinker1,2, Benjamin Maasoumy1, Steffen B Wiegand1, Natalie Filmann3, Christine S Falk4, Katja Deterding1, Kerstin Port1, Carola Mix1, Michael P Manns1,4,2, Eva Herrmann3, Heiner Wedemeyer1,4,2, Anke R M Kraft1,2, Markus Cornberg1,2.
Abstract
This prospective study investigated viral and host markers after stopping long-term therapy with nucleos(t)ide analogues in noncirrhotic patients with hepatitis B e antigen-negative chronic hepatitis B. After stopping therapy, 13 of 15 patients experienced a virological relapse. Rebound of hepatitis B virus DNA and hepatitis B core-related antigen was associated with induction of plasma tumor necrosis factor, interleukin (IL) 10 , IL-12p70, CXCL10 and subsequent decline in hepatitis B surface antigen (HBsAg), with 20% HBsAg loss after long-term follow-up. The peak levels of hepatitis B virus DNA and hepatitis B core-related antigen after cessation of therapy were positively correlated with the level of HBsAg decline at week 48. Thus, stopping or interrupting NA treatment should be further investigated as a strategy to accelerate HBsAg loss.Entities:
Keywords: CXCL10; HBsAg; IP-10; cytokines; hepatitis B virus infection; nucleos(t)ide analogues; stopping treatment
Mesh：
Substances：
Year: 2016 PMID： 27609808 DOI： 10.1093/infdis/jiw412
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226